Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nanoparticle albumin-bound paclitaxel for non-small cell lung cancer. Lansdale: HAYES, Inc.. Directory Publication. 2013 Authors' conclusions Nanoparticle albumin-bound paclitaxel (nab-paclitaxel; Abraxane) is a chemotherapeutic drug that is administered alone or in combination with other agents for the purpose of delaying disease progression and prolonging survival in patients who have non-small cell lung cancer. Nab-paclitaxel differs from standard paclitaxel in that it is a colloidal suspension of 130-nanometers (nm) albumin-bound nanoparticle of paclitaxel and is, therefore, free of solvents. The goal of this new nanotechnology-based formulation is to reduce toxicity and improve the bioavailability of paclitaxel. Indexing Status Subject indexing assigned by CRD MeSH Albumins; Carcinoma, Non-Small-Cell Lung; Lung Neoplasmss; Paclitaxel Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32013000819 Date abstract record published 13/11/2013 |